Emi-Le generated durable responses and encouraging PFS with manageable safety in patients with aggressive adenoid cystic carcinoma.
Diving Into B7-H4 Inhibition to Augment the ACC Treatment Paradigm
Glenn J. Hanna, MD, highlights interim efficacy and safety data from a phase 1 trial of Emi-Le in patients with aggressive adenoid cystic carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
Mirvetuximab Soravtansine/Carboplatin Improves ORR But Fails to Extend PFS in FRα-High Recurrent Ovarian Cancer
2
Neoadjuvant Nivolumab Plus Ipilimumab Yields High PFS, OS Rates in Locally Advanced Cervical Cancer
3
Tolerability and ILD Prevention Drive Second-Line Treatment Sequencing in HER2+ NSCLC
4
FDA Accepts sBLA for Subcutaneous Mosunetuzumab Plus Polatuzumab Vedotin in R/R LBCL
5